
CDDO-Im
CAS No. 443104-02-7
CDDO-Im( RTA-403 | TP-235 | CDDO-Imidazolide )
Catalog No. M24402 CAS No. 443104-02-7
CDDO-Im is an activator of Nrf2 and PPAR (Kis: 232/344 nM for PPARα/PPARγ).
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 65 | In Stock |
![]() ![]() |
10MG | 102 | In Stock |
![]() ![]() |
25MG | 200 | In Stock |
![]() ![]() |
50MG | 320 | In Stock |
![]() ![]() |
100MG | 484 | In Stock |
![]() ![]() |
500MG | 1035 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameCDDO-Im
-
NoteResearch use only, not for human use.
-
Brief DescriptionCDDO-Im is an activator of Nrf2 and PPAR (Kis: 232/344 nM for PPARα/PPARγ).
-
DescriptionCDDO-Im is an activator of Nrf2 and PPAR (Kis: 232/344 nM for PPARα/PPARγ).
-
In VitroCDDO-Im is highly active in suppressing cellular proliferation of human leukemia and breast cancer cell lines (IC50 approximately 10-30 nM). In U937 leukemia cells, CDDO-Im also induces monocytic differentiation as measured by increased cell surface expression of CD11b and CD36. Treatment with CDDO-Im elevates protein levels of Nrf2, a transcription factor previously shown to bind ARE sequences, and increases expression of a number of antioxidant and detoxification genes regulated by Nrf2. CDDO-Im is one of the most potent synthetic triterpenoids shown to induce growth inhibition and apoptosis in various human cancer cells, including multiple myeloma, lung, pancreas and breast cancer. CDDO-Im treatment markedly induces cell cycle arrest at G2/M-phase and apoptosis in the triple-negative breast cancer cell lines, SUM159 and MDA-MB-231. The CD24?/EpCAM+ cells in SUM159 tumorspheres are significantly inhibited by CDDO-Im treatment. CDDO-Im also significantly decreases sphere forming efficiency and tumorsphere size in both primary and secondary sphere cultures.
-
In VivoCDDO-Im is a potent inhibitor of de novo inducible nitric oxide synthase expression in primary mouse macrophages. Moreover, CDDO-Im inhibits growth of B16 murine melanoma and L1210 murine leukemia cells in vivo. Injection of 10 nM (5.4 μg) of CDDO-Im almost completely blocks the ability of IFN-γ to induce iNOS, and treatment with as little as 1 nmol of CDDO-Im (0.54 μg) is partially effective.
-
SynonymsRTA-403 | TP-235 | CDDO-Imidazolide
-
PathwayNuclear Receptor/Transcription Factor
-
TargetKeap1-Nrf2
-
RecptorNrf2|PPAR|PPARα|PPARγ
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number443104-02-7
-
Formula Weight541.72
-
Molecular FormulaC34H43N3O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:50 mg/mL (92.30 mM; Need ultrasonic);Water:Insoluble
-
SMILESC[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)C(=O)N6C=CN=C6
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Place AE, et al. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res. 2003 Jul;9(7):2798-806.
molnova catalog



related products
-
VVD-130037
VVD-130037 is a small molecule activator specifically targeting Kelch-like ECH-associated protein 1 (KEAP1) with potential antitumor activity.
-
K67
K67 competitively inhibits the interaction between Nrf2-ETGE and Keap1, inhibits the proliferation of HCC cells with high expression of S351 phosphorylated p62, and can be used to study cancer.
-
CBR-470-1
CBR-470-1 is a potent inhibitor of glycolytic phosphoglycerate kinase 1 (PGK1) that activates NRF2 by increasing methylglyoxal levels.